We Need to Look Beyond Drugs in Value Assessment
(12/3, Jennifer Bright, Morning Consult) comments “...We must eschew the notion that one method for value assessment exists and instead adopt a transparent, active-learning approach in which all stakeholders collaborate to define and improve methods and models. That includes collaborating with experts in an open-source environment from device manufacturer, surgical societies and other therapeutic communities to investigate the best data sources and methods for evaluating the comparative benefit on clinical, quality-of-life and cost metrics. An open-source approach allows all health care stakeholders to participate in value assessment movement and collaborate on new — more accurate and relevant — methods and models in a manner that speeds economic model development.” Full
Real World Evidence For Rare Diseases: Payers Cite Lack Of Clarity On Value
(12/2, Cathy Kelly, Pink Sheet) reports “...US payers unanimously point to a lack of standardized, or at least interoperable, electronic health records as the biggest obstacle in the application of real world evidence. By comparison, only 34% of European payers cited a lack of standardization of health records as the biggest problem creating uncertainty around the benefits of RWE. Responses to questions around reputable sources of information for any coverage decision point to the need to leverage key opinion leaders who payers trust to drive confidence in RWE, the report suggests.” Paid Subscription Required
Introducing the Engagement Tool and Resource Repository for Patient-Centered Outcomes Research
(12/2, Krista Woodward, MPH, MSW, Ivey Wohlfeld and Alana Cole, The PCORI Blog) comments “...One of the ways that PCORI supports researchers, patients, and stakeholder partners working together is promoting the uptake of engagement practices and methodologies within the broader healthcare research community. That's why we are excited to share our new Engagement Tool and Resource Repository for Patient-Centered Outcomes Research, which we developed to help spread these practices. This peer-to-peer repository houses more than 150 tools and resources—that number will increase over time—that can be used to inform the work of others in the field when planning and conducting PCOR.” Full
Are We Really Measuring Quality?
(12/3, Winston Wong, PharmD, Journal of Clinical Pathways) comments “...I would assert that quality measures should be developed and based on ‘real-world evidence,’ as real-world data and evidence are major inputs into the ‘learning machine,’ which is vital to survive the world of alternative payment models. Quality measures should be at a high enough level to reflect the goals of improved clinical outcomes, improved patient experience, and controlled cost, while allowing the process measures to monitor consistency to treatment guidelines, pathways, and integration of new innovation. Process measurements would then become a tool to be used internally by the practice to identify opportunities to optimize their performance to reach the general quality measure goals.” Full
Common Breast Cancer Treatment Ineffective, Yale Study Finds
(12/3, Maya Geradi, Yale Daily News) reports “...The study is the first evidence that sentinel lymph node biopsies do not benefit patients with a breast cancer called ductal carcinoma in situ, or DCIS...The finding is important, ‘as unnecessary surgery places patients at higher risk for surgical complications and adds to overall healthcare costs,’ according to co-author and Yale associate surgery professor Brigid Killelea...This research, published in the Journal of the National Cancer Institute Cancer Spectrum, was funded by the Patient-Centered Outcomes Research Institute.” Full
Your Health Checkup: Are You Using the Right Medications for Your Heart Condition?
(12/3, Douglas P. Zipes, M.D., Saturday Evening Post) reports “...In a comparative effectiveness cohort study of 167,275 patients with AF, oral anticoagulants such as dabigatran, rivaroxaban, and apixaban were associated with modestly lower fracture risk compared with warfarin, a finding even more pronounced among AF patients who also had osteoporosis. The fracture risk was lowest among apixaban users. Therefore, AF patients who have osteoporosis would seem to be better off taking apixaban than warfarin.” Full
Abarca, Amgen Enter Outcome-Based Agreement For Enbrel
(12/3, Abarca Press Release) “...Under the agreement, Amgen will issue rebates to Abarca's clients for eligible members who discontinue the use of the drug after three months of treatment. This applies to members of commercial health plans who are using the drug for the treatment of moderate to severe rheumatoid arthritis. ‘This is a win for all parties,’ said Jason Borschow, president and CEO of Abarca. ‘It will provide Amgen valuable information about how Enbrel® is utilized, it will lower costs for plans, and it will bring additional benefits to our healthcare system.’” Full
Behavioral Economic Insights to Improve Medication Adherence in Adults with Chronic Conditions: A Scoping Review
Jacqueline Roseleur, et al.
December 2019, The Patient - Patient-Centered Outcomes Research
Long-Term Outcomes of Sentinel Lymph Node Biopsy for Ductal Carcinoma in Situ
Peiyin Hung, et al.
December 2019, JNCI Cancer Spectrum
JNCI Cancer Spectrum